Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 9/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6409405 | 0.99 | CCR5 (0.37) | CCR5MMP1MMP9MMP13ADAM17 | |
| SCHEMBL6410538 | 0.92 | CCR5 (0.37) | CCR5MMP1MMP9MMP13ADAM17 | |
| SCHEMBL6415581 | 0.92 | CCR2 (0.39) | CCR5CCR2 | |
| Hydrochloric Acid SCHEMBL6410534 | 0.91 | CCR5 (0.36) | CCR5MMP1MMP9MMP13ADAM17 | |
| Hydrochloric Acid SCHEMBL6408819 | 0.91 | CCR2 (0.38) | CCR5CCR2 | |
| SCHEMBL6415315 | 0.90 | CCR5 (0.38) | CCR5MMP1MMP9MMP13ADAM17 | |
| SCHEMBL6409601 | 0.90 | CCR5 (0.38) | CCR5MMP1MMP9MMP13ADAM17 | |
| Hydrochloric Acid SCHEMBL6413215 | 0.89 | CCR5 (0.38) | CCR5MMP1MMP9MMP13ADAM17 | |
| Hydrochloric Acid SCHEMBL6408374 | 0.89 | CCR5 (0.38) | CCR5MMP1MMP9MMP13ADAM17 | |
| SCHEMBL6418723 | 0.88 | CCR5 (0.38) | CCR5MMP1MMP9MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR5 4/4885MMP1 873/4885MMP9 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.